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A B S T R A C T
Background: Multi-dose dispensing (MDD) of medications is a health technology designed to promote medica-
tion adherence and patient safety. MDD has been used as an alternative to ordinary prescription dispensing for
patients, mostly elderly with high medication use.
Objective: To evaluate the initiation phase of the MDD service to older adults ≥65 years and assess wheter the
medication use of the new MDD patients is appropriate in terms of drug related problems.
Methods: The European Union EU(7)-PIM list and the Inxbase databases were used for identifying potentially
inappropriate medications (PIMs) and drug-drug interactions (DDIs). The study sample consisted of a total of
208 patients aged 65–108 years who were involved in the MDD service (PharmaService Ltd.) in Finland in
2015–2016. Clinically signiﬁcant diﬀerences of PIM and DDI occurrences were identiﬁed using a Pearson's chi-
square test throughout the demographic groups under study.
Results: Results demonstrate that for 81% of the study participants, at least one medication from the EU (7)-PIM
list was prescribed, and up to 64% of PIMs were clinically signiﬁcant. According to the Inxbase database, ﬁve
patients (2.4%) were prescribed category D clinically signiﬁcant DDIs. Additionally, 61% of the patients saw an
increase in the number of medications prescribed within six months after the initial MDD order.
Conclusions: The results suggest that the MDD service should be accompanied by a regular medication review
tailored to speciﬁc patient groups (i.e., older patients) to avoid potential DRPs.
Introduction
Multi-dose dispensing (MDD) is a health technology designed to
promote medication adherence and patient safety and it is widely used
particularly in the Nordic countries.1–3 With MDD, the regularly used
medicines, usually in per oral formulation, are machine-packed into
unit-dose pouches labelled with the patient's data, medication contents,
and timing of dose intake.2 The service is most applicable for older
patients with multiple medications, those with a limited ability to
maintain appropriate medication use, and whose medication regimen is
not frequently changed.3
There is quite limited evidence on the outcomes of the MDD on
appropriate medication use in older adults.1 MDD service has been
shown to reduce dispensing errors, increase adherence, decrease med-
ication costs, and reduce medication administration time for nurses.3,4
The MDD procedure has found to need more standardization, particu-
larly medication reconciliation and review for MDD patients.1 The MDD
procedure has been recommended to include medication reconciliation
and review to all patients prior their enrolment in the service. Action
should be taken to ensure that the medication list is clinically appro-
priate and matches patient's prescribed medication regimen.1,2 As
minimum, the dosages, administration times of the medications, drug-
drug interactions (DDIs) and potentially inappropriate medication
(PIM) use should be reviewed by the prescriber and the team re-
sponsible for the care of the patient.1 However, few studies have been
conducted to show the risk of using potentially inappropriate medica-
tions (PIMs) by patients on MDD service.4–6 This study will focus on the
initiation phase of the MDD service to older adults ≥65 years and as-
sess whether the medication of the new MDD service users is appro-
priate in terms of PIMs and clinically signiﬁcant DDIs.
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Methods
Study design and method
A retrospective registry-based study was carried out in Finland
where MDD service was ﬁrst launched in 2002 and implemented
through legislation in 2011.7 The service is provided by community
pharmacies who buy the unit-packed pouches primarily from two na-
tionally operating companies.1,2
Within the selected one-month period in September 2015, the
structured register data for this study was derived from PharmaService's
documentation system, ANJA. The patients' selection criteria was the
following: age≥65 years, the ﬁrst MDD order from PharmaService was
made in September 2015, there were no missing data in MDD records
and the service was used at least for the period of the subsequent 6
months.
The records contained anonymous structured information on pa-
tients' gender, age, underlying diseases, and MDD medications (name
and dosage of medications with ATC-code and time of administration).
The MDD-medication lists of the same patients were collected again
after six months from the enrolment in the MDD service for the follow-
up.
The appropriateness of the medications in terms of PIM use was
evaluated manually by comparing the patient's medication list at
baseline and at 6 months to the EU(7)-PIM list.8 If the potential
harmfulness of the medication was dependent on the dose or duration
of the treatment or medication itself, it was taken into account in the
medication review. Identiﬁed PIMs were divided as clinically sig-
niﬁcant (used medications were inappropriate for older patients or it
was used in higher doses and/or longer treatment course as re-
commended) and non-signiﬁcant (medications were used in lower
doses and/or shorter treatment course as considered harmful for older
patients) PIMS. The EU(7)-PIM list was used as a reference because it is
adopted to be used within EU, it is quite recently developed (in 2014)
and it can be used if the available clinical information is minimal.8
The clinically signiﬁcant drug-drug interactions were identiﬁed also
manually by using Inxbase system.9 It was selected as a criteria because
it is routinely used in Finland throughout the healthcare, also in com-
munity pharmacies.10 The Inxbase suggests short, concise and evidence-
based information on more than 20,000 drug interactions that are di-
vided into four levels (A-D) of clinical relevance, where A means minor
interaction and D means interaction that is best avoided.9 In this study,
category C and D interactions were documented, with the main focus on
type D clinically signiﬁcant DDIs.
Data analysis
The structured patient data from PharmaService's documentation
system were entered into MS Excel 2010. Information on PIM use and
DDIs based on medication reviews was also entered into Excel sheet. A
Pearson's chi-squared test was used to assess the inﬂuence of back-
ground variables (age, gender, MDD medications, and the number of
underlying chronic diseases per patient) on the number of PIMs and
clinically relevant interactions.
Results
Study participants
Of the original sample of 622 patients initiating the MDD service,
208 (33%) fulﬁlled the inclusion criteria and were included in the study
(Fig. 1). Of the ﬁnal study participants (n= 208), 69% were female
(Table 1). The mean age of the participants was 84.6 years (range
65–108 years). The patients had on average 2.1 chronic conditions of
which cardiovascular diseases (89% of the participants), Alzheimer's
disease (33%) and severe mental disorders (26%) were most common.
The mean number of prescribed MDD medications and food supple-
ments taken were 5.9 and 1.3, respectively. The most frequently used
groups of medications in treatment schemes were psychoanaleptics
(85%), beta-blockers (64%), and dietary supplements (59%). During
the 6-month follow-up period, the number of medications used in-
creased for 61% of the patients, and in most of the cases at least two
medications and one food supplement had been added to the drug
therapy regimen.
Identiﬁcation of PIMs
At baseline, a majority (n=152; 73%) of the MDD patients used at
least one PIM medication (Fig. 2). For 77% of the study participants
(n= 160), at least one medication from the EU(7)-PIM list was pre-
scribed after the 6-months’ period, and about 62% ((n=122 (59%) for
the ﬁrst month, and n= 134 (64%) after 6 months of using MDD ser-
vice)) of these PIMs were clinically signiﬁcant. With the increase in the
number of medications, the risk of PIMs in the patient's medication list
increased (p < 0.01). PIM users were more likely to take ﬁve or more
medications daily (Table 2). The most common potentially harmful
PIMs were associated with acetylsalicylic acid, pantoprazole, carba-
mazepine and risperidone (Fig. 3).
Prevalence of clinically signiﬁcant DDIs
Prevalence of clinically signiﬁcant DDIs depended on the number of
medications used (p < 0.01) and the number of diseases (p=0.01).
Patients exposed to potential DDIs used ﬁve or more medications daily,
and had four or more chronic diseases (Table 2). According to the In-
xbase database, 104 patients (50%) had category C and only ﬁve pa-
tients (2.4%) had category D DDIs. In total, three D-interactions with
carbamazepine (carbamazepine + nifedipine/quetiapine/risperidone),
one D-interaction of citalopram and sulpiride, and one D-interaction of
spironolactone and potassium were found. The mentioned category D
interactions were identiﬁed both at the ﬁrst and six months after in-
itiating the MDD service.
Discussion
To the authors' best knowledge, this is the ﬁrst study evaluating
drug related problems based on the EU(7)-PIM list and Inxbase data-
bases of older patients using MDD service. Both above listed tools
complemented each other and could be recommended for evaluation of
medication use of older patients in other European countries. In the
present study, there was no control group used. However, a cross-sec-
tional study with the control group (e.g., MDD with and without
medication review included in the service) could be developed to
identify more speciﬁc outcomes and to determine the way forward in
regard to the patients’ safety when using MDD service.
Wallerstedt et al. (2013)4 and Sjöberg et al. (2011)6 reported that
the MDD system increases the number of medications and the ﬁndings
could not be explained by the increased disease burden for patients
with MDD.4,6 The current study supports results of previous research.
However, the mechanism of the increase in the number of medications
during the MDD service remains unclear and needs further research.
The following reasons could be considered for the increased number of
used medications. Firstly, the temporal association between the MDD
and an increased proportion of used medications indicates that the drug
treatment may be more seldom reconsidered and new medications
added. Secondly, the increased adherence to the medications may
manifest in new DRPs such as adverse reactions that need to be treated.
Underlying mechanisms and contributing factors for our ﬁndings can
only be speculated upon, but need further research.
Prevalence of DDIs and PIMs varies considerably in the literature
and depending on the diﬀerences in patient and disease characteristics,
prescribing patterns, and the availability of medications listed in DDI or
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PIM criteria. Some studies indicate that MDD users may be more ex-
posed to PIM use but at the same time have lower probability of po-
tentially dangerous DDIs.6,11,12 The present study showed that up to
64% of the MDD service patients have a risk of clinically signiﬁcant
PIMs, and 2.4% are susceptible to clinically signiﬁcant category D drug
interactions. The most common PIMs were associated with
Fig. 1. Selection of the patients for the study (n= 208).
Table 1
Characteristics of the multi-dose dispensing (MDD) patients (n= 208) included
in the study.
Variable n %
Gender
Female 143 68.8
Male 65 31.2
Age (years)
65–90 174 83.7
> 90 34 16.3
Сhronic diseases
Mean number of chronic diseases per person 2.1
Cardiovascular diseases (at least one condition); e.g., hypertension 186 89.0
Alzheimer's dementia 69 33.2
Severe psychotic and/or other severe mental disorders (at least one
condition)
55 26.4
Type II diabetes 30 25.0
Asthma and similar obstructive pulmonary diseases (at least one
condition)
19 14.4
MDD packed medications and food supplements
Mean number of medications per person (prescription and non-
prescription medicines)
5.9
Mean number of food supplements per person 1.3
Psychoanaleptics (at least one in use); e.g., amitriptyline 176 84.6
Beta blockers (at least one in use); e.g., metoprolol 132 63.5
Dietary supplements (at least one in use); e.g., calcium carbonate 122 58.7
Fig. 2. Patients with PIMs and with no PIMs in the treatment regimen at baseline and after 6 months from entering the MDD service (% of the patients, n= 208).
Table 2
Dependence between the number of pouched medications used, the number of
chronic diseases, the prevalence of potentially inappropriate medications
(PIMs), and the prevalence of C and D class drug-drug interactions (DDIs) based
on the Inxbase database among the multi-dose dispensing (MDD) patients
within 6 months (n= 208).
Patients with no
(clinically signiﬁcant)
PIMs (n=76)
Patients with clinically
signiﬁcant PIMs
(n=132)
All patients
(n=208)
n % n % n %
Number of chronic diseases per person
1–3 68 37.4 114 62.6 182 87.5
4–6 8 30.8 18 69.2 26 12.5
Number of MDD medications used per person*
1–5 41 62.1 25 37.9 66 31.7
5–9 29 24.6 89 75.4 118 56.7
9–13 6 25 18 75 24 11.6
Patients with no DDIs
(n=99)
Patients with DDIs
(n=109)
All patients
(n=208)
n % n % n %
Number of chronic diseases per person*
1–3 93 51.1 89 48.9 182 87.5
4–6 6 23.1 20 76.9 26 12.5
Number of medications used per person*
1–5 46 69.7 20 30.3 66 31.7
5–9 47 39.8 71 60.2 118 56.7
9–13 6 25 18 75 24 11.6
*p < 0.001.
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acetylsalicylic acid with the risk of GI ulcers and bleedings, and clini-
cally signiﬁcant PIMs with pantoprazole taken for a longer period than
recommended with an increased risk of Clostridium diﬃcile infection
and hip fracture. These ﬁndings are consistent with those reported by
Hosia-Randell et al. (2008).12 To decrease number of PIMs compre-
hensive medication review should be properly conducted before en-
tering patients in and regularly during the MDD service.1,2 There could
be developed international guidelines for scheduled medication reviews
of MDD patients where pharmacists could more closely collaborate with
physicians. For more eﬀective evaluation of patients' medication re-
cord, joint regular CPD courses could be developed for diﬀerent
healthcare specialists.
Study limitations
The study excludes data on patients with prescription and non-
prescription medications not included in the MDD service. This may
lead to an underestimation of medication use. The study identiﬁed only
potential DRPs, and consequently, could not conclude how many of
them can cause a manifest DRP, or how many would lead to a change
being made in the drug treatment.
Conclusions
In this study, an MDD service was observed to have an association
with greater frequency of PIM use among older patients in initiation –
common PIM – can become even common within 6 months. Despite the
fact that all patients enrolled in the MDD service are recommended to
Fig. 3. The incidence of the most common potentially inappropriate medications (PIMs) (n) identiﬁed among the patients (n=208) during a 6-month follow-up
period in the multi-dose drug dispensing (MDD) service.
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receive a medication review service, a large proportion of the MDD
patients used at least one PIM. Clinically signiﬁcant DDIs were rela-
tively rare but still of considerable concern. The results suggest that in
the future, MDD services should be accompanied by a regular medi-
cation review tailored to speciﬁc patient groups (i.e., older patients) to
avoid potential DRPs.
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